CN110997722B - Cd38调节抗体 - Google Patents

Cd38调节抗体 Download PDF

Info

Publication number
CN110997722B
CN110997722B CN201880049993.8A CN201880049993A CN110997722B CN 110997722 B CN110997722 B CN 110997722B CN 201880049993 A CN201880049993 A CN 201880049993A CN 110997722 B CN110997722 B CN 110997722B
Authority
CN
China
Prior art keywords
antibody
antigen
seq
binding fragment
acd38
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880049993.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110997722A (zh
Inventor
帕斯卡·梅希尔
安妮·古比耶
凯文·莫尔德
妮娜·艾斯勒
约瑟芬·萨利姆
西蒙尼·菲利斯托
贝特里兹·古耶内切亚·科尔佐
赫曼塔·巴鲁
比安卡·普林兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Black Belt Medical Co ltd
Original Assignee
Black Belt Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Belt Medical Co ltd filed Critical Black Belt Medical Co ltd
Publication of CN110997722A publication Critical patent/CN110997722A/zh
Application granted granted Critical
Publication of CN110997722B publication Critical patent/CN110997722B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880049993.8A 2017-06-08 2018-06-08 Cd38调节抗体 Active CN110997722B (zh)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201762517149P 2017-06-08 2017-06-08
US201762517150P 2017-06-08 2017-06-08
US62/517,149 2017-06-08
US62/517,150 2017-06-08
US201762517164P 2017-06-09 2017-06-09
US201762517740P 2017-06-09 2017-06-09
US201762517753P 2017-06-09 2017-06-09
US201762517734P 2017-06-09 2017-06-09
US201762517745P 2017-06-09 2017-06-09
US201762517165P 2017-06-09 2017-06-09
US62/517,753 2017-06-09
US62/517,745 2017-06-09
US62/517,164 2017-06-09
US62/517,165 2017-06-09
US62/517,740 2017-06-09
US62/517,734 2017-06-09
US201762582666P 2017-11-07 2017-11-07
US201762582653P 2017-11-07 2017-11-07
US201762582681P 2017-11-07 2017-11-07
US201762582676P 2017-11-07 2017-11-07
US62/582,666 2017-11-07
US62/582,653 2017-11-07
US62/582,681 2017-11-07
US62/582,676 2017-11-07
PCT/EP2018/065239 WO2018224683A1 (en) 2017-06-08 2018-06-08 Cd38 modulating antibody

Publications (2)

Publication Number Publication Date
CN110997722A CN110997722A (zh) 2020-04-10
CN110997722B true CN110997722B (zh) 2023-09-26

Family

ID=62620847

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880049993.8A Active CN110997722B (zh) 2017-06-08 2018-06-08 Cd38调节抗体
CN201880049994.2A Active CN110997723B (zh) 2017-06-08 2018-06-08 Cd38调节抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880049994.2A Active CN110997723B (zh) 2017-06-08 2018-06-08 Cd38调节抗体

Country Status (8)

Country Link
US (3) US12343394B2 (cg-RX-API-DMAC7.html)
EP (2) EP3635002A1 (cg-RX-API-DMAC7.html)
JP (3) JP7237951B2 (cg-RX-API-DMAC7.html)
KR (3) KR102719065B1 (cg-RX-API-DMAC7.html)
CN (2) CN110997722B (cg-RX-API-DMAC7.html)
AU (3) AU2018280871B2 (cg-RX-API-DMAC7.html)
CA (2) CA3066553A1 (cg-RX-API-DMAC7.html)
WO (2) WO2018224685A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018280871B2 (en) 2017-06-08 2024-09-26 Black Belt Therapeutics Ltd CD38 modulating antibody
CA3073085A1 (en) 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 modulating antibody
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
AU2020205753B2 (en) 2019-01-11 2025-05-29 Omeros Corporation Methods and compositions for treating cancer
CA3127520A1 (en) 2019-01-23 2020-07-30 Encefa Cd31 competitors and uses thereof
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
EP3947463A4 (en) 2019-03-29 2022-12-21 Arcus Biosciences, Inc. CANCER TREATMENT USING AN IDENTIFIED ADENOSINE IMPRESSION
CN114524877A (zh) * 2019-03-29 2022-05-24 索伦托药业有限公司 结合cd38的经工程改造的变异抗体
EP4211476A4 (en) * 2020-09-10 2024-11-13 CASI Pharmaceuticals, Inc. BLOOD SCREENING PROCEDURES
CN114457028A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd38抗体的多能干细胞及其衍生物与应用
CN114437215B (zh) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 抗人cd38抗体及其制备方法和用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
AU2011202520C1 (en) 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
NZ586780A (en) 2005-03-23 2012-02-24 Genmab As Antibodies against CD38 for treatment of multiple myeloma
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP2799451A1 (en) * 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
KR20150139636A (ko) 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
AU2016228249A1 (en) 2006-09-26 2016-10-06 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2013209322A1 (en) 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
CN101605906A (zh) 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2342220B1 (en) 2008-10-06 2021-05-12 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
BR112012006388B1 (pt) 2009-09-22 2022-01-04 Probiogen Ag Método para produzir uma molécula, e, método para produzir uma proteína
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
MX360336B (es) 2010-07-16 2018-10-30 Adimab Llc Star Colecciones de anticuerpos.
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
GB201300346D0 (en) * 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
BR112015021521A2 (pt) 2013-03-15 2017-10-10 Genentech Inc anticorpos anti-crth2 e métodos para seu uso
WO2015123687A1 (en) 2014-02-14 2015-08-20 Centrose, Llc Extracellular targeted drug conjugates
SG11201607983YA (en) 2014-03-28 2016-10-28 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
KR20170085131A (ko) 2014-12-01 2017-07-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Dna 항체 작제물 및 그 이용 방법
EP3280443B1 (en) 2015-04-08 2022-08-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
PT3313441T (pt) 2015-06-24 2024-05-07 Janssen Biotech Inc Modulação imunitária e tratamento de tumores sólidos com anticorpos que se ligam especificamente a cd38
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
RU2761115C1 (ru) 2015-10-02 2021-12-06 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, специфические в отношении костимуляторного tnf-рецептора
AU2018280871B2 (en) 2017-06-08 2024-09-26 Black Belt Therapeutics Ltd CD38 modulating antibody
EP4036116A4 (en) 2019-09-27 2024-01-24 Nanjing GenScript Biotech Co., Ltd. ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF

Also Published As

Publication number Publication date
AU2018280871B2 (en) 2024-09-26
JP7237951B2 (ja) 2023-03-13
CN110997722A (zh) 2020-04-10
US20210277138A1 (en) 2021-09-09
CA3066553A1 (en) 2018-12-13
AU2018280871A8 (en) 2020-01-30
CN110997723A (zh) 2020-04-10
US12343394B2 (en) 2025-07-01
KR20200021069A (ko) 2020-02-27
US12161717B2 (en) 2024-12-10
KR20250025514A (ko) 2025-02-21
JP7467584B2 (ja) 2024-04-15
JP2023030071A (ja) 2023-03-07
AU2018280869B2 (en) 2025-01-02
EP3635002A1 (en) 2020-04-15
CN110997723B (zh) 2023-09-26
KR102770106B1 (ko) 2025-02-21
AU2025201908A1 (en) 2025-04-03
CA3066555A1 (en) 2018-12-13
KR102719065B1 (ko) 2024-10-17
NZ760448A (en) 2025-03-28
JP7237950B2 (ja) 2023-03-13
KR20200021068A (ko) 2020-02-27
AU2018280869A1 (en) 2020-01-16
EP3635003A1 (en) 2020-04-15
US20250367286A1 (en) 2025-12-04
NZ760342A (en) 2025-03-28
AU2018280871A1 (en) 2020-01-16
JP2020522280A (ja) 2020-07-30
US20230103584A1 (en) 2023-04-06
WO2018224685A1 (en) 2018-12-13
WO2018224683A1 (en) 2018-12-13
JP2020522281A (ja) 2020-07-30

Similar Documents

Publication Publication Date Title
CN110997722B (zh) Cd38调节抗体
JP7596447B2 (ja) Ｃｄ３８調節抗体
CN111032086B (zh) Cd38抗体
CN111032693B (zh) Cd38调节抗体
US11542338B2 (en) CD38 modulating antibody
KR20200019669A (ko) Cd38 조정 항체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: Cheshire

Patentee after: Black Belt Medical Co.,Ltd.

Country or region after: United Kingdom

Address before: Hertfordshire

Patentee before: Black Belt Medical Co.,Ltd.

Country or region before: United Kingdom

CP03 Change of name, title or address